A new clinical trial, co-led by endocrinologist and diabetes expert John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine has shown that the oral form of semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease, and/or chronic kidney disease
What effects are researchers studying when investigating BPC-157 and TB-500
Paying attention to nutrition, hydration and sleep quality can help support more consistent energy during the transition
The peptide promotes M2 macrophage polarization, shifting the immune response from a pro-inflammatory to a pro-regenerative state
These medications are essential for keeping your asthma under control